This was confirmed in a meta-analysis of 15 studies by Xu et al., which included 3104 patients, that showed that the OS and DFS were lower in breast cancer patients with high levels of CXCR4 expression compared to those with low levels of CXCR4 expression [72]. This evidence concerns the gene CXCR4 and breast carcinoma.